All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche, and Sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
On 31st July 2017, the European Medicines Agency (EMA) received a Marketing Authorization Application (MAA) from Kite Pharma for KTE-C19 (axicabtagene ciloleucel) for patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL), transformed Follicular Lymphoma (tFL), and Primary Mediastinal B-Cell Lymphoma (PMBCL) who are not eligible for Autologous Stem Cell Transplant (ASCT).
KTE-C19 is the first Chimeric Antigen Receptor (CAR) T-cell therapy to be submitted to the EMA. In May of this year, KTE-C19 was granted Priority Review by the U.S. Food and Drug Administration (FDA; read more here) and is expected to make a decision on 29th November 2017.
The MAA submission included data from the phase II ZUMA-1 trial (NCT02348216). Primary results from this study were initially presented by Frederick L. Locke at AACR 2017 (view here), then by Sattva S. Neelapu at ICML 2017 (read here), and most recently by Yi Lin at the 22nd Congress of the EHA (click here to read more). Immune signature data of cytokine release syndrome and neurologic events from the trial was also presented by Locke during AACR (view here).
Currently, KTE-C19 is being investigated at the phase II/III stage in Mantle Cell Lymphoma (MCL) in the ZUMA-2 trial (NCT02601313) and ZUMA-8 has been planned in Chronic Lymphocytic Leukemia (CLL).
References
Your opinion matters
Which of the following would most increase your confidence in referring patients with R/R large B-cell lymphoma for CAR T-cell therapy?